Printer Friendly

GLIATECH INITIATES ADCON CLINICAL TRIALS FOR ADDITIONAL INDICATIONS; STUDIES TO TEST PRODUCT EFFECTIVENESS IN INHIBITING ADHESIONS

 CLEVELAND, Sept. 13 /PRNewswire/ -- Gliatech today announced the start of pilot clinical trials of its ADCON(TM) technology to inhibit postoperative adhesions following tenolysis of hand tendons and neurolysis of peripheral nerves. These pilot studies focus on two new applications for the ADCON technology, whose anti-adhesion properties offer a multitude of potential postoperative applications. Pivotal efficacy trials are already under way in lumbar disc surgery.
 "These pilot studies will further confirm the effectiveness of ADCON for these two important indications," said Thomas O. Oesterling, Ph.D., president and chief executive officer of Gliatech. "The successful completion of these studies will be the basis for initiation of pivotal efficacy studies."
 The return of satisfactory finger movement is one of the most difficult and challenging problems following tendon repair hand surgery. The formation of adhesions due to scarring around the tendon results in a reduction of the tendon's ability to glide, thus limiting the range of finger motion. In the peripheral nervous system, postsurgical scar formation can lead to tethering and compression of nerves. This combination results in loss of nerve function and generation of painful sensations. Currently there are no marketed products effective in reducing either postsurgical tendon or peripheral nerve scarring and adhesions.
 There are approximately 90,000 hand tendon surgery procedures performed annually in the United States alone and over 100,000 peripheral nerve surgeries. Many of these are required to treat the effects of industrial accidents; many of the latter are also performed to correct such conditions as carpal tunnel syndrome and other repetitive motion disorders. Both of these surgeries are often multiple-step procedures requiring a series of operations. "The prevention of unwanted scar formation would make subsequent surgeries easier and ultimate recovery faster," said Oesterling.
 The pilot studies will be conducted at two European sites in which ADCON will be applied to the exposed tendons or nerves and compared to appropriate control surgeries. The clinical evaluation will include a range of motion test for the tenolysis study and the measurement of sensitivity and pain for the neurolysis study. These clinical studies follow Gliatech's preclinical tests on a variety of tendon and peripheral nerve models that have shown that ADCON inhibits unwanted scar and adhesion formation with no untoward effects.
 Gliatech is developing a family of ADCON products to inhibit excessive scarring following surgery. Gliatech's first product, ADCON-L, is currently in a pivotal clinical trial in Europe to evaluate its efficacy in the inhibition of excess scarring following lumbar disc surgery. Other products under development include those intended for abdominal, pelvic, cardiac, and implant surgeries. The total market potential for surgical adhesion prevention products in the United States alone is in excess of $1 billion annually.
 Gliatech was formed in 1988 to discover, develop and commercialize therapeutic products based on an understanding of properties of glial cells, a major component of the nervous system.
 -0- 9/13/93
 /CONTACT: Thomas O. Oesterling, Ph.D., president of Gliatech, 216-831-3200, or Anthony J. Russo, Ph.D. of Noonan/Russo Communications, Inc., 212-696-4455, or G. Thomas Gibson of the Gibson Network, Inc., 216-881-9191/


CO: Gliatech ST: Ohio IN: MTC SU:

CK-LG -- NY037 -- 1247 09/13/93 11:21 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 13, 1993
Words:528
Previous Article:AWT/REECO AND M&W INDUSTRIES SIGN AGREEMENT TO MARKET INNOVATIVE VOC-CONTROL TECHNOLOGIES
Next Article:MABON ELECTS BURKE SENIOR VICE PRESIDENT
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters